CBDX (Curative Biosciences) Debt-to-EBITDA : (As of Mar. 2018)

Curative Biosciences  (OTCPK:CBDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Curative Biosciences Debt-to-EBITDA Related Terms

The historical data trend for Curative Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences Debt-to-EBITDA Chart

Curative Biosciences Annual Data
	Trend	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun17
Debt-to-EBITDA		Get a 7-Day Free Trial					-	-	-	-	-

Curative Biosciences Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-

CBDX vs ACUR, CVLB, RDGL: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curative Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biosciences Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curative Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Curative Biosciences's Debt-to-EBITDA falls into.

Curative Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Curative Biosciences's Debt-to-EBITDA for the fiscal year that ended in Jun. 2017 is calculated as

Curative Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2018) EBITDA data.

Curative Biosciences Business Description